Shares of I-Mab (NASDAQ:IMAB – Get Rating) have been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $89.83.
IMAB has been the subject of a number of recent research reports. Piper Sandler lowered their price objective on I-Mab from $90.00 to $80.00 in a research note on Tuesday, March 29th. Zacks Investment Research raised I-Mab from a “sell” rating to a “hold” rating in a report on Friday. Finally, HC Wainwright reduced their target price on I-Mab from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, March 30th.
IMAB opened at $13.21 on Friday. The business has a 50 day moving average of $19.12 and a 200-day moving average of $39.17. I-Mab has a 52 week low of $12.00 and a 52 week high of $85.40.
I-Mab Company Profile (Get Rating)
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune.
- Get a free copy of the StockNews.com research report on I-Mab (IMAB)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for I-Mab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for I-Mab and related companies with MarketBeat.com's FREE daily email newsletter.